ホーム › 乳がん › コネチカット州 › New Haven
New Haven、CTにおける乳がんの臨床試験
New Havenとその周辺地域（約30マイル以内）の拠点で、乳がんに関する38件の研究が参加者を募集しています。研究を開いて、参加資格と連絡方法を確認してください。
公式研究テキスト（英語）
ここで研究参加者を募集していますか？ このページの上部に表示できます — 30日間 $99 →
Phase 3 Study of RLY-2608 + Fulvestrant vs Capivasertib + Fulvestrant as Treatment for Locally Advanced or Metastatic PIK3CA-mutant HR+/HER2- Breast Cancer
被験者募集中第3相
- Yale-New Haven Hospital-Yale Cancer Center, New Haven
A Study of PHST001 in Advanced Solid Tumors
被験者募集中第1相
- Yale Cancer Center, New Haven
The Evaluation of PC14586 in Patients With Advanced Solid Tumors Harboring a TP53 Y220C Mutation (PYNNACLE)
被験者募集中第1/2相
- Yale Cancer Center, New Haven
A Study of HER3-DXd in Subjects With Locally Advanced or Metastatic Solid Tumors
被験者募集中第2相
- Yale Cancer Center, New Haven
A Study of Patritumab Deruxtecan (HER3-DXd) in Combination With Trastuzumab Deruxtecan (T-DXd) in Participants With HR-Positive, HER2-Low or HER2-Ultralow Unresectable or Metastatic Breast Cancer
被験者募集中第1/2相
- Yale University School of Medicine - Yale Cancer Center, New Haven
Beamion BCGC-1: A Study to Find a Suitable Dose of Zongertinib Used Alone and in Combination With Other Treatments to Test Whether it Helps People With Different Types of HER2+ Cancer That Has Spread
被験者募集中第1/2相
- Yale University School of Medicine, New Haven
A Phase 1 Study of IM-1617 in Participants With Advanced Cancer
被験者募集中第1相
- Yale Cancer Center, New Haven
Anti-Ly6E Exatecan ADC M7437 in Advanced Solid Tumors
被験者募集中第1相
- Yale University - Yale University School of Medicine, New Haven
An Investigational Study of BG-75202 Alone and in Combination With Other Therapeutic Agents in Adults With Advanced Solid Tumors
被験者募集中第1相
- Yale Cancer Center, New Haven
Study of AVZO-021 in Patients With Advanced Solid Tumors
被験者募集中第1/2相
- Avenzo Therapeutics Recruiting Site, New Haven
A Study of Sacituzumab Tirumotecan (MK-2870) as a Single Agent and in Combination With Pembrolizumab (MK-3475) Versus Treatment of Physician's Choice in Participants With HR+/HER2- Unresectable Locally Advanced or Metastatic Breast Cancer (MK-2870-010)
被験者募集中第3相
- Yale Cancer Center ( Site 0060), New Haven
A Phase III Study of Dato-DXd With or Without Durvalumab Compared With Investigator's Choice of Chemotherapy in Combination With Pembrolizumab in Patients With PD-L1 Positive Locally Recurrent Inoperable or Metastatic Triple-negative Breast Cancer (TROPION-Breast05)
被験者募集中第3相
- Research Site, New Haven
The CDK4/6 Inhibitor Dosing Knowledge (CDK) Study
被験者募集中第3相
- Smilow Cancer Hospital - Yale New Haven Health, New Haven
- Yale University/Yale Cancer Center/Yale School of Medicine, New Haven
- Smilow Cancer Hospital Care Center - North Haven, North Haven · 7マイル先
- 他2件
Signatera-Guided CDK4/6 Inhibitor Therapy in Breast Cancer
被験者募集中
- Yale Cancer Center, New Haven
Palazestrant in Combination With Ribociclib for the First-line Treatment of ER+/HER2- Advanced Breast Cancer
被験者募集中第3相
- Clinical Trial Site, New Haven
A Study of JNJ-101684362 (HLD-0117) in Patients With Metastatic Breast Cancer
被験者募集中第1相
- Yale University School Of Medicine, New Haven
Evolutionary Clinical Trial for Novel Biomarker-Driven Therapies
被験者募集中第2相
- Yale Cancer Center Clinical Trials Office, New Haven
A Study of Elacestrant Versus Standard Endocrine Therapy in Women and Men With ER+,HER2-, Early Breast Cancer With High Risk of Recurrence
被験者募集中第3相
- Yale New Haven Hospital- Yale Cancer Center, New Haven
Study of ORIC-114 in Patients With Advanced Solid Tumors Harboring an EGFR or HER2 Alteration
被験者募集中第1/2相
- Yale Cancer Center, New Haven
Study of the Bria-IMT Regimen and CPI vs Physicians' Choice in Advanced Metastatic Breast Cancer.
被験者募集中第3相
- Smilow Cancer Hospital at Yale New Haven, New Haven
Evaluating the Addition of Adjuvant Chemotherapy to Ovarian Function Suppression Plus Endocrine Therapy in Premenopausal Patients With pN0-1, ER-Positive/HER2-Negative Breast Cancer and an Oncotype Recurrence Score Less Than or Equal to 25
被験者募集中第3相
- Yale University, New Haven
- Yale-New Haven Hospital North Haven Medical Center, North Haven · 7マイル先
- Smilow Cancer Hospital-Derby Care Center, Derby · 8マイル先
- 他1件
A Study With NKT5097 for Adults With Advanced/Metastatic Solid Tumors
被験者募集中第1相
- Yale Cancer Center, New Haven
TReatment of ADC-Refractory Breast CancEr With Dato-DXd or T-DXd: TRADE DXd
被験者募集中第2相
- Yale University Cancer Center, New Haven
ATEMPT 2.0: Adjuvant T-DM1 vs TH
被験者募集中第2相
- Yale Cancer Center at Yale University School of Medicine, New Haven
- Smilow Cancer Hospital Care center at North Haven, North Haven · 7マイル先
- Smilow Cancer Hospital Care center at Derby, Derby · 8マイル先
- 他1件
Optimizing Surgical Decisions in Young Adults With Breast Cancer
被験者募集中
- Yale Cancer Center, New Haven
Phase 3 Study to Evaluate the Efficacy and Safety of HER2/Neu Peptide GLSI-100 (GP2 + GM-CSF) in HER2/Neu Positive Subjects
被験者募集中第3相
- Yale Cancer Center - Smilow Cancer Hospital, New Haven
Pre-Operative Window of ET to Inform RT Decisions (POWER II)
被験者募集中第3相
- Yale University, New Haven
Phase 1/2 Study of ETX-636 in Participants With Advanced Solid Tumors
被験者募集中第1/2相
- Yale University, Yale Cancer Center, New Haven
Study to Evaluate Biomarkers and Safety of Dapagliflozin Concomitant With Neoadjuvant Therapy
被験者募集中第1相
- Yale Cancer Center Smilow Cancer Hospital, New Haven
Efficacy of Trastuzumab Deruxtecan in Metastatic Breast Cancer With Different HER2 Expression Patterns
被験者募集中観察研究
- Yale Cancer Center, New Haven
I-SPY TRIAL: Neoadjuvant and Personalized Adaptive Novel Agents to Treat Breast Cancer
被験者募集中第2相
- Yale Cancer Center, New Haven
A Study to Learn About the Study Medicine Called PF-07248144 in Combination With Fulvestrant in People With HR-positive, HER2-negative Advanced or Metastatic Breast Cancer Who Progressed After a Prior Line of Treatment.
被験者募集中第3相
- Smilow Cancer Hospital - Yale New Haven Health, New Haven
- Smilow Cancer Hospital - North Haven, North Haven · 7マイル先
- Smilow Cancer Hospital - Derby, Derby · 8マイル先
- 他1件
De-Escalation of Breast Radiation Trial for Hormone Sensitive, HER-2 Negative, Oncotype Recurrence Score Less Than or Equal to 18 Breast Cancer (DEBRA)
被験者募集中第3相
- Yale-New Haven Hospital Saint Raphael Campus, New Haven
- Yale University, New Haven
- Smilow Cancer Hospital-Orange Care Center, Orange · 5マイル先
- 他4件
A Study of PARG Inhibitor ETX-19477 in Patients With Advanced Solid Malignancies
被験者募集中第1/2相
- Yale University, Yale Cancer Center, New Haven
Confirmatory Clinical Evaluation of Novilase® Laser Therapy for Focal Destruction of Malignant Breast Tumors
被験者募集中
- Yale University, New Haven
DAANCE FOR CHEMOTHERAPY-INDUCED NEUROPATHY
被験者募集中第2相
- Yale University, New Haven
The Cancer of the Pancreas Screening-5 CAPS5)Study
被験者募集中第3相
- Yale University, New Haven
First-in-Human Study of Mutant-selective PI3Kα Inhibitor, RLY-2608, as a Single Agent in Patients With Advanced Solid Tumors and in Combination With Endocrine Therapy +/- a CDK4/6 or CDK4 Inhibitor in Patients With Advanced Solid Tumors or Advanced Breast Cancer
被験者募集中第1相
- Yale University, New Haven
他の都市における乳がんの試験
- New York City, NY136件の研究
- Houston, TX126件の研究
- Boston, MA112件の研究
- Nashville, TN81件の研究
- Los Angeles, CA73件の研究
- Edison, NJ68件の研究
- St. Louis, MO64件の研究
- Queens, NY64件の研究
- Durham, NC64件の研究
- Chicago, IL59件の研究
- Philadelphia, PA56件の研究
- Dallas, TX55件の研究
New Havenにおける他の研究
- 非小細胞肺癌41件の研究
- がん（全種類）33件の研究
- 転移性癌23件の研究
- 肺がん22件の研究
- 頭頸部扁平上皮癌22件の研究
- 卵巣がん21件の研究
- 大腸癌20件の研究
- 前立腺がん20件の研究
- 急性骨髄性白血病17件の研究
- アルコール使用障害（AUD）17件の研究
- オピオイド過剰摂取17件の研究
- 膵臓がん16件の研究
ClinicalTrials.govより、2026/10/06時点のデータを取得。各研究には独自の参加資格があり、参加可否は研究チームが決定します。